A mixture of Canadian drug developer Medicago’s experimental COVID-19 vaccine and Britain’s GlaxoSmithKline’s adjuvant, will enter massive human research involving greater than 30,000 volunteers this 12 months, the 2 corporations mentioned on Thursday.
The information comes days after early-stage knowledge confirmed Medicago’s plant-based vaccine candidate produced virus-neutralizing antibodies in all volunteers. A decrease dose of the vaccine can be used for additional trials, Medicago mentioned.
The mid-to-late-stage medical research will take a look at the security and immune response capabilities of a routine involving two doses of the vaccine with GSK’s pandemic adjuvant given 21 days aside, the businesses mentioned.
“Confirmed dose sparing and a excessive immune response as a result of GSK’s adjuvant make us assured of delivering an efficacious vaccine with an appropriate security profile in collaboration with Medicago,” mentioned Thomas Breuer, chief medical officer at GSK’s vaccines division.
Disclaimer: This submit has been auto-published from an company feed with none modifications to the textual content and has not been reviewed by an editor